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of mankind. China and India contain almost three-quarters
of the human race, and they have provided their own medical
education and developed their own medical systems from time
immemorial. It would be impertinent for an ordinary
Western doctor, ignorant as he usually is of what these
countries have to offer in the way of medicine, to say that
it has no value.
We do know that in India the Ayurvedic system of medicine
produces cures which we in the West are unable to explain
on a scientific basis; and the study of man and his mind has
for many years been a preoccupation of Chinese physicians.
On rare occasions a drug from their ancient pharmacopoeia
becomes available to us whose actIOn is explainable and
whose benefits we appreciate. This is sometimes hailed as a
_ new discovery. Recent examples are the derivatives of
RaulVo{fia serpentina, which has been used for many hundreds
of years in India for the control of excitable states and hyper-
tension in the form of extracts of the crude root. In the last
decade various alkaloids isolated from it have become
available to Western medicine. This is only the latest of a
notable line. Quinine furnishes another example. The
treatment of malaria by extracts of cinchona bark was known
for many years to the people of South America, and the story
of its cultivation, extraction and introduction to Europe by
the Jesuit missionaries earned it the name of Jesuits' bark.
From the ranks of medical men occasional thinkers do
emerge who have the intelligence, courage and energy to
flaunt the inhibiting conventions and strike out in a new
direction. These are the undaunted pioneers who press
towards new developments and are not afraid to meet the
challenge of inquiry and research. It is thus of the utmost
importance that the aim of medical training should never
become rigid and narrow, but should always be directed to
developing independent thought.
'THE mSTORY OF MEDICINE IN SOUTH AFRICA'
The first consignment of the History of Medicine in South
Africa, written by Dc. Edmund Burrows, has arrived in the
country. Members will recall that the Medical Association
undertook the production of this book as a service to its
members and to the country.
All members of the Medical Association of South Africa
are entitled to one copy of the work in special de luxe binding
at the preferential price of 25s. (The book, bound in cloth,
will be available to the general public at 63s.). With the
approval of the Medical Association (and in conformity with
the practice of learned societies who publish works of import-
ance to give their members an opportunity of receiving prefer-
ence in obtaining copies), the publisher will send one copy
to every member unless the offer has already been turned
down. All who do not wish to keep it will have the oppor-
tunity to return it after inspection and within a limited time;
we hope that this will not be necessary.
This book is the first comprehensive account of the histori-
cal development of medical practice in South Africa and
traces the fascinating story of the struggle against disease and
.ill-health in this country from its beginnings to the end of the
nineteenth century.
Sponsored by the Medical Association of South Africa,
this work can be regarded as the official history of medicine in
South Africa. The Association confidently expects that every
member will wish to retain such a valuable piece of Africana.
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The development of an effective oral diuretic is an important
step forwards in therapeutics. To date the most effective
diuretic agents have been the organic mercurial compounds
administered by intramuscular injection. These have been
associated with remarkably few side-effects. The very small
mortality rate has occurred generally with intravenous
administration.1 -4 Undesirable effects of the mercurial
diuretics are the development of the salt-depletion syndrome
and of hypokalaemic alkalosis, but the major disadvantage
is the necessity of intramuscular injections. These compounds
when given by mouth are less effective diuretics while increase
in the dosage results in toxic effects, particularly in respect of
the gastro-intestinal system. Axelrod and Pitts5 have suggeste.d
that the mercurial diuretics specifically block the renal tubular
reabsorption of chloride. There is an associated loss of sodium
and water but not of bicarbonate. The potassium loss is
variable.
A completely different biological approach was used with
the introduction of acetazolearnide,· a heterocyclic unsub-
• Diamox.
stituted sulphonamide. It inhibits carbonic-anhydrase activity.
This enzyme normally catalyses the conversion of carbon
dioxide and hydrogen to carbonic acid. When this action is
inhibited in the renal tubule there is depression of sodium and
hydrogen-ion exchange resulting in an increased excretion of
bicarbonate, while titratable acidity and ammonia diminish
or disappear. In addition, potassium normally competes with
hydrogen for excretion and during acetazoleamide administra-
tion the reduction in hydrogen-ion secretion is associated with
an increased tubular secretion of potassium.G, 7 Acetazolea-
mide administration therefore results in the excretion of an
increased volume of alkaline urine rich in bicarbonate wjthout
an increase in chloride. Pari passu a state of hyperchloraemic
acidosis develops. Since there is a reduction in the amount of
bicarbonate filtered by the glomeruli,8 with continued adminis-
tration acetazoleamide soon loses its effect in so far as
bicarbonate excretion is concerned. The reduced capacity
to exchange hydrogen for sodium, however, persists, thus
preventing the correction of the acidosis. In our own experi-
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ence and that of others'· 10 it has been an unsatisfactory
diuretic.
Yet another series of diuretic agents in current use is the
amino-uracils. Aminometradinet is an oral diuretic which is
considered to act by directly interfering with the tubular
reabsorption of sodium and/or chloride. Anorexia, nausea
and vomiting are frequent effects.u More recently amisome-
tradinet has been on trial.12 It appears to be less liable to
produce gastro-intestinal effects, but in our limited experience
has not been as effective as the organic mercurials.
Chlorothiazide is 6-chloro-7-sulphamyl-l, 2, 4-benzo-
thiadiazine-l, I-dioxide-a substituted benzothiadiazine
compound with a free sulphonamide group (Fig. 1). It was
first synthesized by Novello and Sprague.13 It was found to be
a potent carbonic-anhydrase inhibitor in Vitro, yet the drug
in animals has produced a large and almost equimolecular
excretion of sodium and chloride without producing acidosis
or alkalosis.14
In a preliminary report15 we confirmed that the mode of
action of cWorothiazide was similar to that of the organic
mercurial compounds inasmuch as its major action was a
tubular one increasing the urinary excretion of chloride.
Despite its known in vitro action as an inhibitor of carbonic
anhydrase, the slight increase in urinary excretion of bi-
carbonate indicated but slight activity in this respect in man.
Several favourable reports on its use as an oral diuretic have
appeared.16 •21
This communication is concerned with (i) detailed short-
term studies on the mode of action and (ii) the results of






Fig. I. Chlorothiazide (6-cho-
ro-7-sulphamyl-I, 2, 4-ben-
zothiodiazine- I, I-dioxide).
The detailed structure of the
heterocyclic ring of cWoro-
thiazide is not known with
certainty, although available
evidence favours a structure
with the 3, 4 double bond as
the predominant form.
insulin, constant serum levels being maintained by means of a
constant infusion apparatus. In the third patient endogenous
creatinine clearance was used as a measure of the glomerular
filtration rate.
Biochemical Methods. For sodium and potassium, flame
photometry with a Barclay flame photometer using lithium
as an internal standard. For chloride, Schales and Schales'
method.n For carbon dioxide, urinary ammonia, and
titratable acidity, Peters and Van Slyke's method.23 For
insulin, Schreiner's method.24 For creatinine, Bonsnes and
Taussky's method.25 Blood urea and serum proteins were
determined by standard laboratory methods of the Depart-
ment of Chemical Pathology, University of Cape Town.
Results
In all 3 cases the administration of cWorothiazide produced
marked alterations in the electrolyte pattern of the urine.
The changes in cases 18 and 23 are illustrated graphically in
Figs. 2 and 3. The most striking alterations are in the urinary
excretion of sodium and chloride, the chloride excretion
exceeding the sodium. Fig. 4 illustrates the event in case 18.
The increase in urinary chloride begins within t hour and
there is a stepwise increase until a peak is reached 2t hours
after the administration of chlorothiazide. Thereafter the
excretion continues at a high though gradually decreasing
level throughout the duration of the experiment. Sodium
behaves similarly, but potassium increases to a lesser extent
(Fig. 5). Urine volume shows a similar increase. Further
observations have shown that this enhanced excretion con-
tinues for a variable period of time, which is commonly up to
8 hours. In case 18, the glomerular filtration rate remained
unchanged (Fig. 4), while in case 23 there was a slight rise in
the glomerular filtration rate during the first and second
periods following chlorothiazide. Case 22 was followed for
7 hours with hourly periods, and similar electrolyte changes
I. SHORT TERM STUDIES ON MODE OF ACfION
Methods
Studies were carried out in 3 patients. They included one
with hypertensive congestive heart failure (No. 18, Table 11)
and 2 cases of the nephrotic syndrome ( os. 22, 23, Table IV).
All 3 patients had long-standing oedema.
After adequate control periods 2 g. of chlorothiazide were
given by mouth. The effect on the glomerular filtration rate
and the renal excretion of the electrolytes was followed for
2t hours in one patient, for 4t hours in another, and for
7 hours in the third. The duration of the periods was approxi-
mately 20,30 and 60 minutes respectively. Urine was collected
by means of indwelling catheters. The bladder was washed
out with a known volume of sterile distilled water and air
insufflation ensured complete emptying of the bladder. The
urine was collected under toluol and then frozen. Blood was
drawn 2t minutes before the mid-point of each period. Serum
under oil was centrifuged and separated immediately and then
analysed promptly or stored frozen. In the first 2 patients the







Fig. 2. Case 18. This illustrates the marked changes in
urinary electrolyte excretion after 2 g. of chlorothiazide in
a patient with hypertensive heart failure. The glomerular
filtration rate is comparable in the two periods.
Fig. 3. Case 23. The changes in urinary electrolyte excretion
are less pronounced in this case of the nephrotic syndrome.
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Fig. 6. Case 18. HC03 =HCO. in urine, mEq./min. NH.=
ammonia and amino acids in urine, mEq./min. TA=titrat-
able acidity, mEq./min. U vol.=urine volume, ml. This
illustrates the slight changes in urinary bicarbonate, ammonia
and titratable acidity following chlorothiazide.
Fig. 7. Case 28, nephrotic syndrome: Prompt increase in
urinary sodium antl potassium followed O· 5 g. of chloro-
thiazide. On the first day potassium loss exceeded sodium
loss.. Note the rapid development of hypokalaemia.
noted in one patient-before the administration of cblorothia-
zide. The diet was salt-restricted (±30 mEq. per 24 hours)
except in case 4, where the salt intake was unrestricted.
The daily dosage used is indicated in Tables n, ill and IV.
Varying dosage schemes were used. The results in the 33
patients are summarized in Table 1. The relevant clinical
were encountered without significant alteration in the
glomerular filtration rate.
Fig. 6 illustrates the changes in case 18 in the bicarbonate
titratable acidity and in urinary ammonia following the
administration of cblorothiazide. There was a rise in the
urinary pH by the second period in case 18 and a temporary
rise during the first period in case 23
Thus of the cations, apart from sodium, there was a lesser
increase in potassium while there was little change in ammonia
and a slight fall in titratable acidity. Of the anions the striking
chloride increase completely overshadowed the slight rise in
urinary bicarbonate. There was no increase in phosphate
excretion in case 18.
Conclusion. These figures illustrate that the mode of action
of chlorothiazide is primarily on the renal tubule, resulting
in an increase in the excretion of chloride, sodium, and water.
The excretion of sodium and chloride is almost equimolecular
although chloride usually exceeds sodium. The potassium
excretion increases to a lesser extent. There is a slight increase
in the urinary bicarbonate and an associated rise in the pH
of the urine.
ll. CUNICAL EXPERIENCE IN 33 PATIENTS WITH O¥DEMA
All patients, except 2, were admitted to the wards of Groote
Sehuur Hospital. Judgment of the effectiveness of cbloro-
thiazide was made by clinical assessment, by observation of
change in weight, and by urine output in relationship to fluid
intake. In some cases sodium, potassium and chloride excre-
tion was measured. A careful watch was kept on the familiar
pitfalls of routine ward collections of 24-hour urine samples.
In assessing the action of a diuretic, the effects of bed rest,
diet and previous therapy had to be considered; for example,
considerable diuresis and loss of weight while at rest was
Fig. 4. Case 18. Cl=chloride in urine, mEq.jmin. Filt. Cl=
Filtered load, mEq.jmin. GFR=glomerular filtration rate
(CIN), ml./min. U vol.=urine volume, ml. The chloride
excretion increases in stepwise fashion after the administra-
tion of 2 g. of chlorothiazide. The glomerular filtration rate
and the filtered load of chlorine remain relatively constant.
The rise in pH is illustrated on this chart. (The true urine
volume is less 40 ml.jperiod-the volume of bladder rinse.)
Fig. 5. Case 18. CI=chloride in urine, mEq.jmin. Na=
sodium in urine, mEq.jmin. K=potassium in urine, mEq.j
min. U vol.=urine volume, ml. The sodium and chloride
excretions follow each other. There is a slight increase in
potassium excretion as well. The potassium scale is larger
than that of the sodium and the chloride.
• One with associated constrictive pericarditis
features and the response in the patients with cardiac, hepatic
and renal oedema are summarized in Tables n, ill and IV.
Examples of effective chlorothiazide therapy are illustrated
in Figs. 7, 8, 9 and 10.
Of the 21 cases with cardiac oedema (Table IT) 11 were due
to rheumatic heart disease, 3 to each of ischaemic heart
disease and hypertensive heart disease, and 1 to each of
syphilitic aortic incompetence, subacute cor pulmonale,
chronic cor pulmonale, and right heart failure in a grossly
obese subject with pulmonary hypoventilation. There was a
good response in 13 patients; this was assessed by significant
weight loss, by a diuresis of up to 3 litres in the succeeding
24 hours, sodium loss of up to 400 mEq. over the same time,
and clinical improvement. In 2 the response was assessed
as fair, in 2 doubtful. In 4 patients there was no response at
all; 3 of these had chronic rheumatic valvular disease with
gross congestive heart failure (8, 9 and 11) and the 4th (16)
had· intractable congestive failure following myocardial
infarction. Cases 9 and 11 were moribund at the time of
treatment. Case 8, who was in acute congestive heart failure,
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TABLE U. CARDIAC OEDEMA 0
JVP LI.er mCll
cm. enlar/le· Blood Maximum Loss or '"Cl
A/le
Duralloll above Creps. men/, Serum urea Dose, sodium gain III r-t'
No. Ra"e Sex Diagnosis Oedema 01 oedema an/l/e 01 bases fin/l'" a/bumln m/l'/ /l.24/hr loss weight Response Remarks Cll
01 breadlhs /l./Ioo m/. looml. '2ftl Ib./ 13Louis down days f{
1 B F 42 Rh., MI ++ 2 yr 10+ + 3 3·8 ~1-23 1-2 (b) 160 -H/12 Good Previously refract~ to Mersalyl. '1:1 C M 44 Rh., MS ++ mths ~ + 2 3'7 4O-? 2x - -12/10 Good Poor response to ersaly) before adm.
3 B M ~8 Rh, MI, AI + ~ mth (a) 10+ + 3 3·8 43-3~ I - -7l/8 Good Refractory to Mersalyl before adm. f-'
4 E F 47 Rh, MI, AI + mths 6 ++ 2 4·3 33-12 2 (c) 166'6 -7/8 Good Complicating S.B.E. suspected. (J:)
~ C M 48 Rh, MS, AS, ++++ 1 wk I~ + I 3'1 67-60 I - -8/4 Good Complicating S. B.E. suspected. 01
Al 00
6 C M 54 Rh, MS, MI ++++ 8 mth 10+ - 4 2·8 16-32 2 (b) 433 -11/7 Good See Fig. 8.
7 E M ~2 Rh, MI, AI ++++ mths 10+ ++ ~ 3'4 ?-130 2·1 - -4?/3 Good Later refractory to ~ g. daily.
8 C M 13 Rh, MS, MI ++++ 2 wk (a) 10+ ++ ~ - 18·~0 1·2 (b) ~6 04 None Responded beller after Mersalyl.
9 B F 40 Rh, AS ++ I mth + 4 ++ 2 3'6 3~-91 2 (c) - +2/10 None Refrnctory to all treatment.
(a)
10 B M 44 Rh, Al ++++ yrs ~ ++ 4 2'2 102-1~8 2 (d) - -2~/7 Fair Refractory to all treatment.
11 C F 67 Rh, MI ++ 2 mth (a) 10+ ++ 2 3·8 81-32 2 (c) - +ll/9 None Previously poor reSI,onse to Mersalyl. m
12 C M 51 S. AI + 2 wk 5 + 3 - 103·39 2 (c) - -2t111 Fair
13 B M 49 Chron. Cl' ++++ 3 yr 10+ ++ 4 - 61-37 I - -7/6 Good Previously poor response to Mersalyl. P>-14 B F 53 PE,Cp + I wk 4 ++ 3 3'8 10-20 1 - -2t/7 Good Possible underlying fibro-elastosis.
15 E M 54 M lnf. ++ 1 yr 4 - 1 4'4 ~5-~2 I - -6/14 Good Claimed beller than Mersalyl.
16 E M 60 M Inf. ++ IIlths 10+ ++ 3 4'4 38-? I - +2/7 None Refractory 10 Mersalyl.
17 E M ~4 IHO + 2 wk 6 ++ 2 3·9 58-~1 1 ~d) - -51/5 Good Poor response to Mersnlyl. t-3
18 E M 51 EH ++++ IIlths 10 ++ 3 3'7 30-50 2 d)(b) - -101/6 Good No elTect on hypertension. 0<19 C M 12 MH, URD ++++ mth. 10+ ++ 3 - 28-? 2 - -1/2 Doubtful Later nephrcctomr; performed.
20 C F 46 MH ++ 4 mth 4 ++ 3 3·8 33·34 I - -1/2 Doubtful Diuresis 3 litres a ter single dose. t:l
21 B M ~I HS,O ++ 8 yr 6 ++ 7 3'9 41-51 2 (d) - -11/8 Good KCI Iherapy because long administration. Ui
~
::ll....
TABLE IJI. HEI'ATIC OEDEMA "l
32 C M 30 Cirrhosis of ++++ 3/12 9 + I 2'7. 26 2 (d) 160 -41-/7 Good Liver biopsy confirms diagnosis. -<the Liver





TABLE IV. RENAL OEDEMA Z
t":l
Serum Maximum Loss Of t":l
Duration Serum choles- Hnt.ma.. Blood sodium golll III
UiNo. Race Sex Age SusfJected Oedema 01 Hyp.,· albumin lerol furia u,.ea Dose, loss weigill RtMpOlIse Remark.,
Aetiology oedema tension g./loo m/. mg./ micro.. mg'; 6./24I1r IIIEq./ Ib./ ~
100 ml. sc~~c lOOml. 2411r • dar Cl
22 D F 29 TypeIl ++++ 1 yr No 2'5 682 78-43 2 (d) 116 -11/14 Initially Later rerrnctory to all Ihctapy. Zgood
23 B F 41 Type 11 ++++ 4 mtll No 2·3 480 Nn 48-50 2 93·1 -5/7 Initially Laler rerractory 10 all therapy. Fall in t:l
good serum potassIUm rrom 4' 2 to 3' 2. t":l
24 E F 12 Type Il ++ 5 mlh No 2·7 357 No 21-7 1-2 (d) - +t!12 None Refractory to steroid therapy
25 C P 53 Type 11 ++++ I mth No 2·7 605 No 40·? 2 (b) - +It/7 None Rerractory to all Iherapy.
26 E M 2 Type Il ++++ 3 wk No 0·6 760 No 25-42 Hd~ - +1 /6 None Refractory 10 all therapy.
27 E F 2 Type 11 ++++ 4 mlll No 1·9 550 No 17-53 1 (d - -p None Refractory to all therapy
28 B F 6 Type 11 ++ + I yr Vc. 0·9 840 Ves 20-40 t 63'1 -6/6 Good Hypokalaemic alkalosis developed.
29 C M 32 Type I ++ 10 mth Ves 2· 3 370 No 47-94 I (_) - -31/7 Good Confirmed by renal biopsy.
30 C M 29 Type I ++++ I IIltll No 2·8 395 Ves 253-255 1 - -21/5 Fair Autopsy confirms diagnosis.
31 B M 53 Ois.d. lupu. ++++ 9 mtb Ves 2'3 567 Vc. 50-64 2 52'5 -1t!4 None Died 3 months later with massive oedema.
eryth. RefraclOry lo all lreatment.
(a)-Previously in CCF. (b)-Intermillent omission of daily dose. (c)-Every third day (d)-
In 2 doses, a.m. and p.m. (_)-Alternate dnys.
JVP-Jugular venous pressure. Rh-Rheumalic heart disease. MI-Mitral incompetence.
MS.,.Mitral stenosis. AI-Aortic incompetence. AS-Aorlic stenosis. S-Syphilis. CP-
Cor pulmonale. PE-Pulmonary embolism. M Inr-MyoCllrdinl infarction. IH-
Ischaemic heart disease. EH ""'l Essential hypertension. M H - Mnlignant hypertension.
UR-Unilaternl renal disease. HS-Hypovenlilalion syndrollle. a-Obesity, Types I and Il
-Type. I and Il nephritis. SBE-Subacute bacterial endocarditis. Under Race, B-
European. C-Coloured, n-Bantu.
Wbere 2 blood-urea fiaures are aiven tbey refer to values before and after treatment. (J:)
CJ,:l
"'l
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Fig. 8. Case 6. Congestive cardiac failure-mitral valve disease. A=weight, lb. B=urine Na
(black columns) and K (white columns), mEq.j24 hrs. C=urine volume, litres. Digitalis therapy
was associated with a loss of sodium, but the addition of chlorothiazide in 2·0 g. dose was associated
with a striking increase in urinary sodium to as much as 400 mEq" per day. The sodium loss from
single doses appeared to continue for at least 48 hours. PotassIUm excretion was relatively un-






Beyer et a/.a have stated that in vitro studies have shown that
chlorothiazide is 30 times more potent a carbonic-anhydrase
inhibitor than acetazoleamide and therefore it is surprising to
find that in man its action in this respect is extremely poor.
It resembles the mercurial group of drugs in that its prime
effect is on the renal tubule with excretion of chloride and
sodium. Others have confirmed these effects. In addition we
have noted the rapid development of hypokalaetTiic alkalosis
following chlorothiazide therapy, an effect which again
resembles the action of the mercurial diuretics.
There are, however, points of difference. We have noted
possible potentiation of the action of the mercurial diuretics,
and, more important, in some cases chlorothiazide was
effective when mersalyl had failed. While the effects on the
restricted diet resulted in a loss of sodium, potassium and chloride
in the urine"· The sodium loss in the 3 subjects amounted to
64, 155 and 69 mEq. respectively.
Our experience with the use of chlorothiazide in the manage-
ment of hypertension is too. limited to state any definite con-
. clusions. In 6 patients with essential hypertension the drug alone
appeared to be associated with a significant fall in blood pressure
in only one and, in that instance bed rest and a low-sodium diet
had been maintained for only 1 week. In 2 other patients receiving
mecamylamine the administration of chlorothiazide was associ-
ated with a further fall in blood pressure and the dose of mecarny-
lamine had to be reduced. Harrington et al. 27 have ascribed this




showed no weight alteration, an unimpressive diuresis, but a
sodium loss of 58 mEq. in 24 hours.
Of 10 cases with the nephrotic syndrome (Table IV) 7 were
due to type-II nephritis, 2 to type-I nephritis, and 1 to dis-
seminated lupus erythematosus. The response was good in
4 and fair in 2. In 4 there was no response at all; there was no
obvious reason for this; the serurn-electrolyte concentrations
were normal but measurements of the glomerular filtration
rate were not available in most of these patients.
One patient with cirrhosis of the liver responded well, and
another with constrictive pericarditis and cirrhosis of the liver
also responded well (Table Ill).
Two cases with the nephrotic syndrome (22 and 23) and
2 with cardiac oedema (7 and 15) responded initially and later
became refractory. Four patients with cardiac oedema (1, 2,
3 and 13) were clearly resistant to mersalyl and responded well
to chlorothiazide. Case 25 with the nephrotic syndrome had
responded to mersalyl but did not respond to chlorothiazide.
Case 8 with cardiac oedema responded .moderately well to
mersalyl but had had chlorothiazide on the previous day-
during which he excreted 56 mEq. of sodium. A potentiating
action is a possible explanation. This also might have been
the case in one other patient.
There were no side-effects. No patients complained of
anorexia, nausea or vomiting and there was no evidence of
leucopenia or liver or renal damage except for a rise in blood-
urea concentration in some of our patients. Two of these pa-
tients, with congestive heart
failure, were moribund and
the 3rd had disseminated
lupus erythematosus. In
3 patients with the
nephrotic syndrome daily
measurement of the protein
loss in the urine showed no
alteration during chloro-
thiazide therapy.
Studies of serum electro-
lytes in most of the patients
before and after treatment
showed little change. A fall
in serumpotassium con- ZID
centration was noted in
9 patients and was moderate
except in cases 28 and 32,
where levels of 2·3 and /I"
2·f) mEq. per litre were
recorded at the end of
therapy.
(Apart from the use of
chlorothiazide in patients with
oedema we have administered
the drug to one patient with
periodic paralysis and a few
patients with hypertension.
1n the case of periodic
paralysis the administration
of I g. of chlorothiazide after
42 days on a low-sodium diet
(26 mEq. per day) re ulted in
the loss of 270 mEq. of
sodium in the urine. The
administration of O· 5 g. of
chlororhiazide to 3 normal
ubjects on a similarly sodium-
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any advantage over a single dose administered in the morning.
A single dose of 1·G-2·0 g. was administered daily in 12 adult
patients. In 8 of them 1·0 g. daily produced an adequate
response, while in 4 other<; 2·0 g. daily appeared to be more
satisfactory. However, 1,0-2·0 g. every third day appeared
to be an effective therapeutic regime in certain patients and
carried less risk of hypokalaemia. The unsupervised pro-
longed use of this drug may be dangerous; and dosage may
well have to be altered repeatedly to suit individual patients.
It is obvious that chlorothiazide is an oral diuretic which
is effective in many cases of cardiac, renal and hepatic oedema.
In our judgment it is frequently as effective as the organic
mercurials administered parenterally in their usual doses.
In this series of 33 patients the drug appeared to be devoid of
toxic effects. The rapid development of hypokalaemic alka-
losis, especially when the drug is given daily, should be borne
in mind (Fig. 7). While Laragh er al. '7 noted that mild to
moderate hypokalaemic alkalosis developed in most of their
32 patients, this complication was less frequently encountered
in our patients. This may be attributed to the fact that, where-
as their patients were maintained on a diet rigidly restricted to
not more than 12 mEq. of sodium per 24 hours, our patients
were receiving not more than 30 mEq. per 24 hours. Sherlock
et al.,%9 however, have reported the occurrence of hypokalaemia
in patients with cirrhosis of the liver and ascites on a dietary
sodium intake of 22 mEq. daily, while Bayliss et al. 30 state that
hypokalaemia might develop during intermittent treatment
when chlorothiazide is
given on 4 consecutive
days each week, and
could be induced in
patients having a sodium
intake of 214 mEq. per
day! On occasions,
however, in some of our
patients, potassium loss
exceeded the sodium loss
(Fig. 10). In cases with
marked sodium deple-
tion it is to be expected
that the predominant
cation excreted would be
potassium rather than
sodium. Hypokalaemia
may be dangerous, not











The wider spacing of
doses, viz., 1-2 g. every
third day or 1-2 g.
daily for, say, 3 day
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Fig. 9. Case 1. Congestive heart failure-mitral incompetence. A=Weight, lb. B=urine a (black
columns) and K (white columns), mEq./24 hrs. C=urine volume, litres. Even with the initial dose
of 0·5 g. of chlorothiazide the marked and prompt increase in the utinary sodium loss is evident. 2·0 g.
produced a pronounced naturesis. The potassium excretion increased only slightly.
Fig. 10. Case 22. A=Weight, lb. B=urine Na (black columns) and K (white columns), mEq./24 hrs.
C=urine volume, litres. The prompt effect of chlorothiazide on sodium and water excretion in a patient
with the nephrotic syndrome is clearly evident. Note, too, the marked increase in potassium loss. This
patient later became refractory to chlorothiazide.
IHI






excretion of water, sodium, chloride and potassium are very
similar to those which are encountered after the administra-
tion of the organic mercurial diuretics the rise in urinary pH is
unlike mercurial action. In addition Beyer%B states that chloiO=
thiazide is markedly active under experimental conditions of
sodium bicarbonate alkalosis, while the mercurial diuretics
are essentially ineffective under these conditions. Further-
more 'BAL'· has no effect on chlorothiazide diuresis whereas
it markedly depresses the sodium and chloride excretion
induced by the mercurial diuretics. Laragh et alY has noted a
further point of difference in that 'free' water clearance is
increased in mercurial-induced diuresis but not in chloro-
thiazide-induced diuresis. Apart from these differences we
have observed that in case 22, where amisometradine failed to
induce a diuresis when given in adequate dosage (up to 3·2 g.
daily), chlorothiazide was immediately effective. It is possible
that its mechanism of action on the renal tubule differs not
only from that of the mercurial diuretics but also from that
of the amino-uracil diuretics.
The diuresis starts within 2 hours of administration of the
drug and the duration of action usually extends maximally
over the next 8 hours, but there seems to be a prolongation of
the effect for a full 24 hours and in an occasional case to
48 hours (Fig. 8). While some have recommended that the
dose should be divided into a morning and an afternoon dose,
this method of administration does not appear to us to have
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ment, may be advisable. In cases recelvmg protracted
heavy dosage the development of listlessness, apathy, weak-
ness and diminution or loss of tendon reflexes should be
watched for, serum electrolyte concentrations should be
determined, and monitoring with the electrocardiogram for
the changes of hypokalaemia is advisable.
There appear to be a few contra-indications to the use of
chlorothiazide in oedematous patients, as follows: (1) Pre-
existing hypokalaemia and (2) marked elevation of the blood-
urea concentration (although several of our patients with
blood ureas ranging between 50 and lOO mg. % received
chlorothiazide without obvious deterioration). (3) In patients
with cirrhosis of the liver and ascites it should be administered
with caution. Sherlock et al. 29 have emphasized the develop-
ment of hypokalaemia in such patients with, in some, the
appearance of hepatic foetor, tremor, confusion and, in one
case, the loss of consciousness-the usual features of hepatic
pre-eoma and coma.
It is clear that certain patients with oedema who responded
well initially became refractory to treatment. The reasons for
this are not apparent. Certain patients who were refractory
to all other diuretic therapy did not respond to chlorothiazide
even in doses of as much as 5·0 g. daily. We have little reason
to recommend a dose above a maximum of 2·0 g. daily.
SUMMARY
1. Short-term studies in 3 patients suggest that chloro-
thiazide acts by inhibiting the renal tubular reabsorption of
chloride and sodium. In this it resembles the organic mer-
curial diuretics, but there is a rise in urinary pH and a slight
increase in the urinary bicarbonate.
2. Clinical experience in 33 patients with oedema is
reported. The results indicate that in a high proportion of
cases it is an effective oral diuretic. A maximum daily dose
of 1-2 g. is advisable in the adult. This may be given as a
single dose or twice daily.
3. In this series of patients chlorothiazide administration
was devoid of toxic effects. The main complication is hypo-
kalaemia, and this may necessitate supplementary potassium
chloride and the adjustment of the dosage schedule to the
requirement of a particular patient. Prolonged unsupervised
use of the drug is to be avoided.
4. Patients may become refractory to chlorothiazide after
having previously responded well.
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THE EMERGENCY TREATMENT AND TRANSPORT OF PATIENTS
WITH RESPIRATORY FAILURE
A. B. BmL, n.A., F.F.A.R.C.S. and P. J. HORRIGAN, M.B., CH.B., Department of Anaesthesia,
Groote Schuur Hospital and University of Cape ~own
Acute respiratory failure may occur in a number of conditions
and may vary in severity from a minor degree of impairment
of respiratory exchange to complete cessation of breathing.
The most obvious and serious concomitant of such failure
is anoxia, with all of its secondary manifestations on the
cardiovascular and central nervous systems. Less often
thought of, but yet of as great importance, is the consequent
inadequate elimination of CO2, which may produce effects
as disastrous as those due to lack of oxygen.
The conditions most commonly associated with acute
respiratory insufficiency are the following:
1. Poliomyelitis involving the muscles of respiration and/or
the muscles of the pharynx and larynx.
2. Polyneuritis, e.g. infective and that due to porphyria.
3. Head injuries.
4. Injuries of the upPer Cervical region of the spmal cord.
5. Poisoning, e.g. from narcotics, insecticides of the anti-
cholinesterase group, shellfish which have ingested poisonous
plankton (see below).
6. Respiratory paralysis deliberately induced as a thera-
peutic measure, e.g. in cases of tetanus.
The occurrence of recent casesl ,! of fatal paralytic mussel
poisoning has re-awakened interest in this uncommon condition
and has shown that here is another cause of acute respiratory
failure which the practitioner may.be called upon to treat.
Mussels and clams may become poisonous when they have
strained the dinoflagellate plankton Gonyaulax out of the
water; the poison has been shown to be a neuromuscular toxin
with effects on both skeletal muscle (curare-like) and peri-
pheral nerves. 3 In addition the poison is said to have a
